
The development of zzso zzso has led to renewed interest in the use of zzso to treat zzso zzso Unfortunately, treatment with unmodified zzso has been zzso zzso with unmodified zzso has been limited by the failure of host zzso mechanisms to eliminate zzso tumor cells and by the emergence of zzso cells lacking the target zzso The use of zzso as carriers of zzso has the potential for overcoming both these limitations because the zzso will be directly zzso and a zzso bound to a cell surface will deliver radiation to adjacent cells lacking the target zzso Experimental and clinical therapy trials of zzso zzso zzso have yielded promising results with both zzso zzso and with zzso against differentiation zzso Bone zzso toxicity has been dose zzso Bone zzso support will most likely be required for the treatment of leukemia and zzso due to the zzso involvement with zzso zzso In the case of solid tumors, bone zzso infusion may allow administration of zzso doses of zzso zzso Although at an early stage in development, zzso zzso have the potential for contributing significantly to the therapy of zzso zzso 

